300289，重大资产重组！

Core Viewpoint - The company Lideman is planning to acquire up to 70% of the shares of Beijing Xiansheng Xiangrui Biological Products Co., Ltd., which will allow Lideman to gain control over Xiansheng Xiangrui and enhance its competitive position in the IVD (in vitro diagnostics) sector, particularly in tuberculosis diagnosis and treatment [2][3][4]. Group 1: Transaction Details - Lideman has signed a framework agreement with shareholders of Xiansheng Xiangrui to acquire the shares through cash payment [3]. - The target company specializes in biopharmaceutical manufacturing, focusing on in vivo diagnostic reagents and human vaccines, particularly for tuberculosis screening and treatment [3][4]. - The funding for the acquisition will come from Lideman's own funds and bank loans, with the transaction price yet to be determined [3][4]. Group 2: Strategic Rationale - The acquisition is expected to add tuberculosis diagnosis and treatment capabilities to Lideman's existing IVD business, thereby strengthening its overall competitiveness and aligning with the interests of the company and its shareholders [4]. Group 3: Financial Performance - In the first quarter of 2025, Lideman reported revenue of 78.91 million yuan, a year-on-year decrease of 16.61%, and a net loss attributable to shareholders of 1.25 million yuan [5]. - Despite recent financial challenges, Lideman's stock has seen a significant increase of over 44% since April 8, with the latest share price at 5.87 yuan, bringing the total market capitalization to 3.2 billion yuan [5].